Skip to main content
OpenTrials
Completed

NCT Number: NCT03456687

Effects of Exenatide on Motor Function and the Brain

The purpose of this research study is to investigate how the brain and motor behavior changes Parkinson's Disease (PD) over time in response to Exenatide. In previous clinical trials, PD patients have experienced symptomatic improvement on Exenatide and literature suggests it may help slow the progression of Parkinson's. Both will be evaluated in this study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–77 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Laboratory for Rehabilitation Neuroscience

Gainesville, Florida, 32611, United States

About this study

Participants will receive baseline testing to confirm a diagnosis of Parkinson's Disease and to determine eligibility in the research study. All of the participants in this study will receive the study drug (Exenatide). The study drug will be provided at the end of the first visit, and participants will be administered the drug once per week for the duration of the study (1 year).

During the research study the following test may occur: (1) questionnaires about quality of life and depression; (2) tests to measure strength and motor function; (3) tests to measure cognition; (4) orientation session to learn a precision gripping task; (5) functional MRI scan of the brain; (6) structural MRI scan of the brain.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients clinically diagnosed with Parkinson's disease (PD) through use of the UK PD brain bank diagnostic criteria
  • early stage PD patients within 5 years of diagnosis who have never taken Exenatide for any reason
  • PD patients with a Hoehn and Yahr stage less than or equal to 2 when on medication
  • patients able and willing to sign informed consent.

Exclusion criteria

  • individuals who have any type of implanted electrical device (such as a cardiac pacemaker or a neurostimulator)
  • individuals with a certain type of metallic clip in the body (i.e., an aneurysm clip in the brain)
  • claustrophobia
  • women who are or might be pregnant and nursing mothers. Pregnancy tests will be carried out for each female subject prior to the MRI scan.
  • psychiatric disorders or dementia
  • other neurologic and orthopedic problems that impair hand movements and walking
  • individuals actively participating in another trial of a device, drug or surgical treatment for Parkinson's disease
  • individuals who have a history metalworking involving cutting processes such as grinding, filing, shaving, and threading, will need radiological clearance to participate in this study. Specifically, individuals who report a history of metalworking will be referred to Radiology at Shands University of Florida(UF) for an orbitofrontal x-ray.
  • individuals who have sustained an eye injury involving metal will also be referred to Radiology at Shands UF for an orbitofrontal x-ray.
  • prior stroke or brain tumor
  • cognitive impairment as assessed by a Montreal Cognitive Assessment score < 23
  • individuals unwilling to comply with the study procedures
  • history of gallstones, digestion problems (such as gastroparesis), severe gastrointestinal disease, history of pancreatitis, a thyroid tumor or cancer, pancreas tumor, or kidney problems
  • severely impaired renal function with creatinine clearance less than 30 ml/min
  • hyperlipidemia defined as more than two times the upper limit of normal
  • body mass index less than 18.5
  • previous exposure to Exenatide
  • diabetes

Treatment and study plan

exenatide

Drug

Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).

Other names: Bydureon, Glucagon-like peptide-1 receptor agonist

Primary outcomes

  1. Change in free-water accumulation in the substantia nigra

    Time frame: Baseline and one-year

    12-month study in PD to watch the effect of Exenatide on the progressive increase of free-water accumulation in the substantia nigra.

  2. Change in blood oxygen level-dependent(BOLD) signal in the posterior putamen.

    Time frame: Baseline and one-year

    12-month study in PD to watch the effect of Exenatide on BOLD signal in the posterior putamen.

  3. Change in blood oxygen level-dependent(BOLD) signal in M1.

    Time frame: Baseline and one-year

    12-month study in PD to watch the effect of Exenatide on BOLD signal in M1.

  4. Change in blood oxygen level-dependent(BOLD) signal in the supplementary motor area(SMA).

    Time frame: Baseline and one-year

    12-month study in PD to watch the effect of Exenatide on BOLD signal in the SMA.

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

Registry information

Important dates

Study start
2018
Primary completion
2020
Study completion
2021
First posted
Mar 7, 2018
Registry last updated
Sep 16, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.